A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays. - Wikidata - wikimedia - TriplyDB

A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.

A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.

http://www.wikidata.org/entity/Q33653774

about

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells Construction and characterization of highly infectious full-length molecular clones of a HIV-1 CRF07_BC isolate from Xinjiang, China A Naturally Occurring rev1-vpu Fusion Gene Does Not Confer a Fitness Advantage to HIV-1.Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing.Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate.Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7 Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies Measuring HIV fusion mediated by envelopes from primary viral isolates.Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design.Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity.Primary infection by a human immunodeficiency virus with atypical coreceptor tropism Unusual Fusion Proteins of HIV-1 Regulation of human immunodeficiency virus type 1 (HIV-1) mRNA translation.Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.

P2860

Q27644515-F4315E8A-7CD9-4B03-A02D-1DECA85A45EA Q28302792-AB5AA805-8FBF-4E6D-853C-4C80224B3C08 Q28535848-BFDF11C0-7F70-40D0-A590-45C69C64FB89 Q30381208-471BED99-2B29-4BA6-9552-4BBE6A2E13FF Q34742873-446DFF36-EFD5-49D3-81FB-99A5380EE7A8 Q35580892-507D1779-9BCD-4355-A7EF-F71C1151E4F8 Q36000722-3BCB1CBF-FAD8-4C35-813B-905550C7FE07 Q36262823-F8AF7D16-9216-4D1B-AE6A-4458B5B94640 Q36585516-3BC34489-9E09-4C1D-A09A-B4662B55D192 Q36827377-0752C484-E0B2-438C-8527-E1C101FCF9C4 Q36978861-C2CEDA5D-D46B-494A-87AC-A6CF70052A56 Q37644079-31D95027-573D-4568-A40E-DBFD571418A9 Q38631923-6BC94FE2-389A-4A86-8362-1F49F19C5358 Q39101871-FAF8431A-96CA-40BD-B1A7-3FF3D4FDEAA0 Q39241455-B0929FC0-5EB4-4853-81C8-95858D3EE013 Q40134111-0F03B88A-2D9D-468D-AC7F-086B20877810

P2860

A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.

http://www.wikidata.org/entity/Q33653774

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A rev1-vpu polymorphism unique ...... tivity in pseudotyping assays.

@ast

A rev1-vpu polymorphism unique ...... tivity in pseudotyping assays.

@en

type

label

A rev1-vpu polymorphism unique ...... tivity in pseudotyping assays.

@ast

A rev1-vpu polymorphism unique ...... tivity in pseudotyping assays.

@en

prefLabel

A rev1-vpu polymorphism unique ...... tivity in pseudotyping assays.

@ast

A rev1-vpu polymorphism unique ...... tivity in pseudotyping assays.

@en

P1433

Q33653774-9FE56A07-9820-4189-81E3-150A6BAE8145

P1476

Q33653774-33B8FBBA-B195-43CE-ACC4-8ACC7287A21E

P2093

Q33653774-01072895-1A00-4EBA-A209-62F46C773188

Q33653774-1BE6DCCA-BBA5-43C7-8D59-ED26F8F5A843

Q33653774-4F64AB81-E90E-40F3-A8EE-A56DE2BF8C0A

Q33653774-7E351A72-95D4-4766-812A-D5E5B3568564

Q33653774-C4386B82-E220-48F7-9471-2972D2783663

Q33653774-DB238068-9C4F-49E7-8586-014E1DCE89CF

Q33653774-FA1CE04D-22D1-4044-9F91-3649983BC29F

P2860

Q33653774-08ACCC29-EC4A-49C6-8450-EAEFA09AF8CE

Q33653774-09CEC4E5-9405-4FC2-A559-DD2C1195706A

Q33653774-0C3FB8CC-C595-4234-AB68-FC7DCEABB6D0

Q33653774-158F9F65-D000-4F99-B639-2895A5B707C5

Q33653774-17955B3D-9918-4C4E-9F96-5CF102F11F40

Q33653774-1E23C9DD-F65A-4F37-8424-A7A675031A89

Q33653774-20E8C328-D11A-4C09-BCC8-2C850AA71CEE

Q33653774-29FEB858-044A-403F-820C-907FD3EA73FD

Q33653774-2B8FCA83-325C-4BD6-B638-3C6C5FE50D9D

Q33653774-2E373631-EA97-4BA6-91B0-A94198BCC028

P304

Q33653774-784C0545-AA71-453C-8975-4E59D50351DC

P31

Q33653774-AF3D7120-5CED-4CB1-B5F6-5E8917D6EE1B

P356

Q33653774-A2C88D41-06AD-4DCA-A79F-95F7C1A6D321

P407

Q33653774-0B6381B5-89A7-4214-844F-5715792C69D1

P433

Q33653774-3D661EE5-349F-4BF9-A663-FBD13E963213

P478

Q33653774-E592FCA9-F09F-4522-8B5B-F4B80923B287

P50

Q33653774-305B7D69-D8EE-4F01-9942-88F326127A2D

Q33653774-34EE7ED5-0B06-4E81-9958-F8080F42D7BC

Q33653774-616CB54F-622C-4652-AFA7-71FDD49B94DC

Q33653774-994D827B-880D-44F8-B0A3-D6FF9FE208A7

Q33653774-AD7A3FA9-CD60-48A6-9772-0B20FAED3967

Q33653774-B278BB4F-FB00-4334-8810-2F2C994887E1

Q33653774-FA7EE506-015B-4B53-B60C-C87C1E5A8BE5

P577

Q33653774-6B8B7DAA-967A-403A-A48F-5D2A6187BCC6

P5875

Q33653774-78A8524F-80E1-4027-A2BA-ADA53C8D517B

P698

Q33653774-6BF94564-FDDB-4F33-BBFD-BA0630A26216

P932

Q33653774-22A48DBB-F4BF-4D7C-9C35-0E97D13C3C30

P356

J.VIROL.2009.11.019

P1433

P1476

A rev1-vpu polymorphism unique ...... tivity in pseudotyping assays.

@en

P2093

David T McPherson

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Anderson

http://www.w3.org/2001/XMLSchema#string

Julie M Decker

http://www.w3.org/2001/XMLSchema#string

Katharina S Shaw

http://www.w3.org/2001/XMLSchema#string

Li-Hua Ping

http://www.w3.org/2001/XMLSchema#string

Matthias H Kraus

http://www.w3.org/2001/XMLSchema#string

Truman Grayson

http://www.w3.org/2001/XMLSchema#string

P2860

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

Regulation of human immunodeficiency virus env expression by the rev gene product

Antibody neutralization and escape by HIV-1

Initiation of translation in prokaryotes and eukaryotes

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

HIV-1 accessory proteins--ensuring viral survival in a hostile environment

P304

346-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VIROL.2009.11.019

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

397

http://www.w3.org/2001/XMLSchema#string

P50

Beatrice H. Hahn

Nicholas F Parrish

Jesus F Salazar-Gonzalez

Ronald Swanstrom

Carolyn Williamson

P577

2009-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40681855

http://www.w3.org/2001/XMLSchema#string

P698

20003995

http://www.w3.org/2001/XMLSchema#string

P932

2822091

http://www.w3.org/2001/XMLSchema#string